

# Prevalence and Antibiotic Sensitivity Pattern of Methicillin-Resistant- *Staphylococcus aureus* in Kathmandu Medical College –Teaching Hospital

Pandey S. , Raza M. S. , Bhatta C. P.

Department of Microbiology, Nobel Medical College Teaching Hospital, Biratnagar and Kathmandu Medical College Teaching Hospital, Kathmandu, Nepal.

**Correspondence address:** Ms. Santwana Pandey, Department of Microbiology, Nobel Medical College Teaching Hospital, Biratnagar- 2, Nepal Phone no. 9841959893

**E-mail:** Santwana\_11@hotmail.com

## Abstract

**Introduction:** *Staphylococcus aureus* is found to be a major source of community as well as hospital acquired infection. Staphylococcal isolates from tertiary care hospital are found to be resistant to commonly used antimicrobial agents. Methicillin resistant *S. aureus*(MRSA) with intrinsically developed antimicrobial resistance has been associated with an increase in morbidity and mortality of the patients in the hospital. This study was undertaken to know the antibiotic sensitivity pattern of staphylococcal isolates with special reference to Methicillin resistant *S. aureus*.

**Methods:** Clinical specimens received from July 2009 to July 2010 in Kathmandu Medical college-Teaching Hospital were processed and all *S. aureus* isolates were included in the study. The isolates were identified by standard laboratory procedure. The antibiotic susceptibility pattern of all staphylococcal strain was determined by modified Kirby Bauer antibiotic sensitivity method.

**Results:** Of 111 *S. aureus* isolates 29(26.12%) were identified to be MRSA. The rate of multi drug resistance was 75.86% for MRSA and 6.09% for MSSA. All the staphylococcal isolates were resistant to penicillin. However, all strains were sensitive to vancomycin.

**Conclusions:** This study showed a high prevalence of MRSA in tertiary care hospital of Kathmandu valley. Regular surveillance of hospital-associated infection and monitoring of antibiotic sensitivity pattern is mandatory to reduce MRSA prevalence in hospital and its spread to community as well. Present study conclusively shows that vancomycin remains the first choice of treatment for MRSA infection. To preserve its value, use of vancomycin should be limited to those cases where there are clearly needed.

**Key words:** MRSA, MSSA, Antibiotic Sensitivity, Vancomycin, *Staphylococcus aureus*

## Introduction

*S. aureus* remains a potent human pathogen, since it is one of the most common cause of nosocomial as well as community acquired infection.<sup>1</sup> It is also the most significant pathogen known for causing sporadic infections and epidemics.<sup>2</sup> Most of the *S. aureus* infections are caused

by Methicillin- sensitive *S. aureus* strains (MSSA) that are usually susceptible to major classes of anti-staphylococcal antibiotics. But Resistance to multiple antibiotics among the staphylococci isolates in hospitals has been recognized as one of the major challenges in hospital infection control.<sup>3</sup>

In the recent years, the widespread use of antibiotics has

undoubtedly accelerated the evolution of MRSA and led to the emergence of strains that have systematically acquired multiple resistance genes.<sup>4</sup> With the current emergence of multi-drug resistant MRSA in hospitals on the one hand<sup>5</sup> and the dramatically increased incidence of hyper-virulent community-associated MRSA on the other hand, MRSA has been able to evolve rapidly and create new clinical problems.<sup>6</sup> These strains are frequently implicated in serious infections and nosocomial outbreaks, which appear to be disseminated globally in adult, pediatric, and neonatal intensive care units (ICUs).<sup>7</sup>

The prevalence of MRSA infection varies depending on the characteristics and size of the hospital. In Australia, 31.9% of *S. aureus* samples taken from 32 laboratories from all states and territories of the country were resistant to methicillin.<sup>8</sup> The number of infections with MRSA in United States hospitals alone rose to nearly 369000 in 2005.<sup>9</sup> While study done in India also shows prevalence rate as high as 31.1% in clinical samples.<sup>10</sup> In an earliest study from Nepal, Rai et al.<sup>6</sup> found that 29% of *S. aureus* isolates were resistant to methicillin.<sup>11</sup>

MRSA are usually found to be resistant to most commonly used antibiotics against staphylococcal isolate. In fact, many stains of MRSA exhibit resistance to both  $\beta$ -lactams and aminoglycosides.<sup>12</sup> These strains are seen possessing elevated resistance to a wide range of antibiotics, limiting the treatment options to very few agents such as vancomycin and teicoplanin.<sup>13</sup> Hence, knowledge of prevalence of MRSA and MSSA and their antimicrobial profile becomes necessary in the selection of appropriate empirical treatment of these infections and controlling nosocomial infection. This study was done to know the antibiotic sensitivity pattern of staphylococcal isolates with special reference to Methicillin resistant *S. aureus* at KMC Teaching Hospital.

## Methods

Clinical specimens from July 2009 to July 2010 received in clinical microbiology lab of KMC Teaching Hospital were processed and all *S. aureus* isolates were included in the study. One hundred and eleven (111) isolates of *S. aureus* were collected from culture samples received from different departments of the hospital. The isolates were consecutive and non repetitive (One per patient). One sample from one patient was inclusion criteria of study data, second sample from other site of same patient was not considered for study.

In Microbiology Lab, samples were cultured on Blood, Mac-Conkey, and Chocolate agars for 24-48 hours. Samples for blood culture were inoculated in Brain Heart Infusion broth and subcultured on 24 and 72 hours on

Blood, Mac-Conkey agar. Identification of organisms was carried out by standard laboratory operating procedures.<sup>14</sup> (Gram staining, Catalase test, Mannitol fermentation, Slide coagulase and Tube coagulase test).

The antibiotic susceptibility pattern of all the strains was determined by modified Kirby Bauer disc diffusion method against the following antibiotics: penicillin (10 units), gentamicin (10mcg), erythromycin (15mcg), tetracycline (30mcg), co-trimoxazole (25mg), amikacin (30mcg), cephalexin (30mcg), ciprofloxacin (5mg) and vancomycin (30mg). For identification of MRSA, oxacillin discs (1unit) obtained from Hi-Media Laboratories Pvt. Ltd. was used. A zone of inhibition less than 10 mm. or any discernible growth within zone of inhibition was indicative of methicillin resistance. *S. aureus* ATCC 25923 was used as a standard control strain. Methicillin resistance was confirmed for all the MRSA isolates by the agar screening method using Mueller Hinton agar supplemented with 4% NaCl and 6  $\mu$ g/L of oxacillin.<sup>15</sup>

Multidrug resistance (MDR) is defined for this report as resistance to three or more antimicrobial classes. Statistical analysis tool (SPSS17) was used to calculate P-value (<0.05 significant) was calculated using Pearson Chi Square test.


## Results

Out of 111 *S. aureus* isolated from various clinical specimen. Highest number of isolates was from pus and wound swab and least number from urine. (**Table 1**) 29 (26.12%) of isolates were MRSA (**Table 1**). Out of 29 MRSA isolated 22(75.86%) were MDR strain. Only 5(6.09%) among 82(73.87%) MSSA were MDR strain (**Fig. 1**).

**Table 1:** Distribution of *S. aureus* and MRSA in various clinical specimens

Clinical specimen	No of <i>S. aureus</i> isolate (%)	MRSA (%)
Pus and wound swab	87 (78.37)	25 (28.73)
Blood	19 (17.11)	3 (15.78)
Urine	05 (04.50)	1 (20.00)
Total	111 (100)	29 (26.12)

## Prevalence and Antibiotic Sensitivity Pattern of Methicillin- Resistant



**Fig 1:** Detection of multidrug resistance in MSSA and MRSA

**Table 2:** Antibiotic resistance pattern of MRSA and MSSA

Antibiotic	MRSA		MSSA		P-value
	Number(n=29)	%	Number(n=82)	%	
Penicillin	29	100	82	100	N/A*
Oxacillin	29	100	00	00	0.0001
Vancomycin	00	00	00	00	N/A*
Gentamicin	06	20.68	05	0.6	0.024
Amikacin	07	24.13	02	2.43	0.001
Co-trimoxazole	13	44.82	17	20.07	0.012
Tetracycline	06	20.68	09	10.97	0.188
Cephalexin	22	75.86	25	30.48	0.0001
Erythromycin	13	44.82	07	8.53	0.0001
Ciprofloxacin	05	17.03	14	17	0.984

## Discussion

MRSA has emerged as a serious threat to public health worldwide. It has added to the burden of patient by prolonging hospital stay and increasing morbidity and mortality rate. Present study showed prevalence rate of MRSA to be 26.12%. Another study done in Kathmandu valley by Shrestha et. al. reported 44.9 % as MRSA from nosocomial *S. aureus*.<sup>16</sup> Rajbhandari et. al. also reported 54.9% MRSA isolates at Bir Hospital.<sup>1</sup> Study done in Eastern Nepal showed comparable result of 26.14% MRSA.<sup>17</sup> While recent study done in Bharatpur, Nepal had made known worrisome isolation rate of 39.6%.<sup>18</sup> MRSA was isolated at the rate 75.5% from clinical samples in a

The antimicrobial susceptibility pattern of MRSA and MSSA isolates against antimicrobial agents are summarized in Table 2. More than 25% of MRSA isolates were resistant to penicillin, oxacillin, cephalexin, co-trimoxazole, erythromycin. Least amount of resistance was observed in vancomycin (0%) ciprofloxacin(17.03%) tetracycline and gentamicin (20.68%). Last but not the least amikacin (24.13%).  $\beta$ -lactam antibiotics like penicillin (100% resistance) and cephalexin (30.48% resistance) were found to be ineffective against MSSA too. Rest of the antibiotic showed less than 20% resistance towards the isolated MSSA.

study conducted by Rijal et. al. in Pokhara Valley.<sup>19</sup> Similar study done in western parts of Nepal by Tiwari et. al. also had shown alarmingly high rate of MRSA isolate (69.1%) which the authors has attributed to indiscriminate use of antibiotics and its accessibility in these<sup>20</sup>

Above studies show considerable variations between institutions, often in the same geographical areas, exist, demonstrating that MRSA prevalence, in some settings, significantly exceeds previous estimate. There could be many explanations for these differences: infection control measures, antibiotic prophylaxis and treatments used in each ward/hospital and, not less important, the clonal and often epidemic nature of these microorganisms.<sup>21, 22</sup>

Present study also shows maximum number of *S.aureus* and MRSA isolation from pus and wound swab (25/29) ascertaining the role of the organism as cause of pyogenic infection. This is similar to the study done in Nepal, Bharatpur, India and Pakistan.<sup>16, 18, 20, 23, 24</sup>

Analysis from previous studies revealed a relationship between methicillin resistance and resistance to other antibiotics<sup>16, 18, 22, 24</sup>. This study showed that all MRSA isolates were significantly less sensitive to antibiotics as compared with MSSA isolates. Significant difference (P-value < 0.05) was observed in case of oxacillin, gentamicin, amikacin, co-trimoxazole, cephalaxin, erythromycin. However, the difference observed in case of tetracycline and ciprofloxacin was statistically insignificant (P-value > 0.05). Homogeneous insusceptibility to beta-lactams like penicillin and cephalaxin, characteristic MRSA was also observed in our study. This may be due to presence of intrinsically developed β lactamase in MRSA strain. It also showed the high resistance to cotrimoxazole and erythromycin as these antibiotics are usually used at random to cure generalized and pyogenic infection.

Antimicrobials such as amikacin, gentamicin and tetracycline with resistance less than 25% could be used against of MRSA infection. But due to their mode of action, have limited use for empirical therapy of MRSA related infection.

Resistance to ciprofloxacin was observed to be 17.93% in this study. Limiting its indiscriminate use and doing antibiotic susceptibility testing it could be considered as a drug of choice for MRSA infection and can be recommended for empirical therapy in this setting

The multi-drug resistant phenotype is a particular characteristic of the methicillin-resistant *S.aureus* strains. It has added to the burden of hospital personnel to control infection associated with MDR-MRSA. Present study shows alarmingly high rate of MDR strain among MRSA isolates (75.86%). Studies conducted in eastern and western part of Nepal also have reported MDR- MRSA to be as high as 65-78%.<sup>16, 19</sup> Indian literature also shows the isolation of MDR-MRSA as high as 77%<sup>23</sup>

Though these MDR strains are not found with additional virulence properties, their characteristic multidrug resistance restricts the options available to treat infections caused by this organism.<sup>24</sup>

Vancomycin a glycopeptides seems to be the only antimicrobial agent which showed 100% sensitivity through all parts of Nepal and may be used as the drug of choice for treating multidrug resistant MRSA infections. But its toxic side effects like renal impairment and prohibitive

cost has limited its use. When vancomycin is considered for treatment, choice inevitably requires the need for in vitro susceptibility testing of every isolate of MRSA in the clinical laboratories owing to emergence of Vancomycin resistant *Staphylococcus aureus* (VRSA) in various parts of world.

## Conclusion

In view of the high rates of isolation of MRSA and its resistance to penicillin, erythromycin, cephalexin, and trimethoprim, treatment of MRSA infections in this province with these antibacterial agents would be unreliable. Vancomycin remains the first choice of treatment for MRSA infection world wide and to preserve its value, use of vancomycin should be limited to those cases where there are clearly needed. Further, the regular surveillance of hospital associated infections including monitoring antibiotic sensitivity pattern of MRSA and MSSA and formulation of definite antibiotic policy may be helpful in reducing the incidence of MRSA infection. Our study is an opening to facilitate epidemiologists to understand the nature of MRSA isolates in this part of Nepal.

## References

1. Rajbhandari R, Manandhar SP, Shrestha J. Comparative study of MRSA and its Antibiotic Susceptibility pattern in indoor and outdoor Patients of Bir Hospital. N J M. 2003; 1: 62-65.
2. Baddour MM, Abuelkheir MM, Fatani AJ. Trends in antibiotic susceptibility patterns and epidemiology of MRSA isolates from several hospitals in Riyadh, Saudi Arabia. Ann Clin Microbiol Antimicrob. 2006; 5: 30.
3. Majumder D, Bordoloi JS, Phukan AC, Mahanta J. Antimicrobial susceptibility pattern among methicillin resistant staphylococcus isolates in Assam. Indian J Med Microbiol. 2001; 19:138-140
4. Stefani S, Varaldo PE. Epidemiology of methicillin-resistant staphylococci in Europe. Clin Microbiol Infect. 2003; 9(12):1179-86.
5. Sakoulas G, Moellering RC Jr. Increasing antibiotic resistance among methicillin-resistant *Staphylococcus aureus* strains. Clin Infect Dis. 2008; 46( 5):360-7
6. Valentini P, Parisi G, Monaco M, Crea F, Spanu T, Ranno O, Tronci M, Pantosti A. An uncommon presentation for a severe invasive infection due to methicillin-resistant *Staphylococcus aureus* clone USA300 in Italy: a case report. Ann Clin Microbiol Antimicrob. 2008; 7:11.

## Prevalence and Antibiotic Sensitivity Pattern of Methicillin- Resistant

7. Berthelot P, Grattard F, Fascia P, Fichtner C, Moulin M, Lavocat MP. Implication of a healthcare worker with chronic skin disease in the transmission of an epidemic strain of methicillin-resistant *Staphylococcus aureus* in a pediatric intensive care unit. *Infect Control Hosp Epidemiol.* 2003; 24:299-300.
8. Nimmo GR, Pearson JC, Collignon PJ, Christiansen KJ, Coombs GW, Bell JM. Prevalence of MRSA among *Staphylococcus aureus* isolated from hospital inpatients, 2005: report from the Australian Group for Antimicrobial Resistance. *Commun Dis Intell.* 2007 ;31(3):288-9
9. Spurgeon D. Prevalence of MRSA in US hospitals hits new high. *BMJ* 2007; 335:961
10. Rajaduraipandi K, Mani KR, Panneerselvam K, Mani M, Bhaskar M, Manikandan P. Prevalence and antimicrobial susceptibility pattern of methicillin resistant *Staphylococcus aureus*: A multicentre study. *Indian J Med Microbiol.* 2006; 24:34-8
11. Rai SK, Talukder NR, Shrestha HG. Methicillin resistant *Staphylococcus aureus* in a tertiary Medical Centre, Nepal. *Indian J Med Microbiol.* 1990; 8:108-110.
12. Thornsberry C. The development of antimicrobial resistance in staphylococci. *J Antimicrob Chemotherap.* 1998; 21 (Suppl.C):9-16.
13. Brumfitt W, Hamilton-Miller J. Methicillin-resistant *Staphylococcus aureus*. *New Engl J Med.* 1989; 320:1188-96
14. Betty AF, Daniel FS, Alice SW. *Staphylococcus, Micrococcus and Similar Organisms*, Chapter 19. In: Baily and Scott's Diagnostic Microbiology, 11th edn. (Mosby Inc: St. Louis); 2002. p 284.
15. National committee for clinical laboratory standards. Performance standards for Antimicrobial Disk susceptibility tests. 7th ed. Villanova PA, 2000: M2-A7.
16. Shrestha B, Pokhrel BM, Mohapatra TM. Phenotypic Characterization of nosocomial isolates of *Staphylococcus aureus* with reference to MRSA. *J Infect Dev Ctries.* 2009; 3(7):554-560
17. Kumari N, Mohapatra TM, Singh YI. Prevalence of Methicillin-Resistant *Staphylococcus aureus* (MRSA) in a Tertiary-Care Hospital in Eastern Nepal. *J Nepal Med Assoc.* 2008; 47: 53-56
18. Sanjana RK, Shah R, Chaudhary N, Singh YI. Prevalence and antimicrobial susceptibility pattern of methicillin –resistant *Staphylococcus aureus* in CMS –teaching hospital : Preliminary report. *JCMS– Nepal* 2010; 6(1): 1-6
19. Rijal KR, Shrestha N, Pahari N, Shrestha B, Paudel B, Nepal A, Ghimire P, Rijal B. Methicillin resistant *Staphylococcus aureus* in patients visiting Western region hospital. *JIOM.* 2008; 30(1):21-25
20. Tiwari HK, Das AK, Sapkota D , Sivrajan KK , Pahwa VK. Methicillin resistant *Staphylococcus aureus*: prevalence and antibiogram in a tertiary care hospital in western Nepal. *J Infect Dev Ctries.* 2009; 3(9):681-4
21. Stefani S, Varaldo PE. Epidemiology of methicillin-resistant staphylococci in Europe. *Clin Microbiol Infect.* 2003; 9(12):1179-86
22. Robinson DA, Enright MC. Multilocus sequence typing and the evolution of methicillin-resistant *Staphylococcus aureus*. *Clin Microbiol Infect.* 2004; 10(2):92-7.
23. Saikia L, Nath R, Choudhury B, Sarkar M. Prevalence and antimicrobial susceptibility pattern of methicillin-resistant *Staphylococcus aureus* in Assam. *Indian J Crit Care Med.* 2009; 13: 156-8
24. Voss A, Doebbeling BN. The worldwide prevalence of methicillin resistant *Staphylococcus aureus*. *Int J Antimicrob Agents.* 1995; 5: 101- 106
25. Arora S, Devi P, Arora U, Devi B. Prevalence of Methicillin-resistant *Staphylococcus aureus*(MRSA) in a Tertiary Care Hospital in Northern India *J Lab Physicians.* 2010 ; 2(2): 78-81
26. Subedi S. and Brahmathan K. N. Antimicrobial susceptibility patterns of clinical isolates of *Staphylococcus aureus* in Nepal. *Clin Microbiol Infec.* 2005; 11: 35-7